Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 Diabetes
Launched by NOVO NORDISK A/S · Nov 4, 2011
Trial Information
Current as of June 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects with insulin requiring type 1 or type 2 diabetes for at least 24 months
- • Current treatment with human insulin (either premix of short and long/intermediate acting insulin) in a twice daily treatment regimen preparation and/or self-mix for at least 12 months
- • Body mass index (BMI) below or equal to 35.0 kg/m\^2
- • HbA1c below or equal to 11.0%
- Exclusion Criteria:
- • Total daily insulin dose at least 1.4 IU/kg
- • Treatment with oral hypoglycaemic agents within the month prior to inclusion
- • Recurrent severe hypoglycaemia (as judged by the investigator)
- • Active proliferative retinopathy
- • Impaired renal function with creatinine at least 150 mcmol/l (1.7 mg/dl)
- • History of pancreatitis
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company headquartered in Denmark, specializing in the research, development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapies. With a strong commitment to improving patient outcomes, Novo Nordisk invests significantly in clinical trials to advance scientific knowledge and develop effective therapies. The company is dedicated to sustainability and ethical practices, striving to deliver high-quality healthcare solutions while addressing the evolving needs of patients worldwide. Through collaboration and innovation, Novo Nordisk aims to lead the way in transforming diabetes and other chronic diseases into manageable conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ayr, , United Kingdom
Livingstone, , United Kingdom
Watford, , United Kingdom
Graz, , Austria
Berlin, , Germany
Ulm, , Germany
Dublin, , Ireland
Birmingham, , United Kingdom
Kettering, , United Kingdom
Leicester, , United Kingdom
Northampton, , United Kingdom
Nottingham, , United Kingdom
Whiston, , United Kingdom
Bern, , Switzerland
Newcastle, , United Kingdom
Schwedt, , Germany
Bolton, , United Kingdom
Jena, , Germany
Neunkirchen, , Germany
Saarlouis, , Germany
Bath, , United Kingdom
Würzburg, , Germany
Dublin 9, , Ireland
Bristol, , United Kingdom
Hamburg, , Germany
Wien, , Austria
Anklam, , Germany
Cottbus, , Germany
Erkner, , Germany
Leipzig, , Germany
München, , Germany
Quakenbrück, , Germany
Rostock, , Germany
Cork, , Ireland
Blackburn, , United Kingdom
Paisley, , United Kingdom
Patients applied
Trial Officials
Global Clinical Registry (GCR,1452)
Study Director
Novo Nordisk A/S
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials